long intergenic non-protein coding RNA 1486Genealiases: []
Q-omics provides the consensus-scored LINC01486 profile across patient tissues and cancer cell-line models. LINC01486 expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, LINC01486 is differentially expressed in 1, with the highest sampling consensus in COAD. Additionally, LINC01486 RNA expression shows 6,621 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight MESO, COAD, and STAD as cancer lineages where LINC01486 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01486 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01486 survival associations across molecular data types. LINC01486 RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01486 RNA expression–survival associations across cancer types. High LINC01486 expression shows unfavorable associations in MESO, KIRC, ACC, LIHC and STAD, but favorable associations in UVM. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for LINC01486 RNA expression.
This table summarizes LINC01486 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01486. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01486 shows lower tumor expression in COAD. The COAD box plot shows higher LINC01486 RNA expression in normal versus tumor tissue (log2 FC = −0.036, t-test p = .016).
This table shows molecular features associated with LINC01486 in patient tissues and cancer cell lines. In patient samples, LINC01486 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
